首页 / 院系成果 / 成果详情页

Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26) 期刊论文

编号：

116B53E01C27597DBCF5535F1B9F382F
作者：

Wei, Juying#^[1]Cai, Qingqing#^[2]Zhang, Liling^[3];Zou, Liqun^[4];Li, Zengjun^[5];Zhou, Keshu^[6];Wu, Huijing^[7];Qiu, Lihua^[8];Su, Liping^[9];Ding, Kaiyang^[10];Zhou, Hui^[11];Yu, Li^[12];Li, Fei^[13];Li, Wenyu^[14];Lin, Li'e;Xiao, Qing^[16];Wang, Erhua^[17];Jing, Hongmei^[18];Zheng, Meifang^[19];Zhang, Hongyu^[20];Gao, Yuhuan^[21,22];Gao, Da^[23];Chen, Lijia^[24];Jin, Jie*^[1]
语种：

英文
期刊：

BLOOD CANCER JOURNAL ISSN：2044-5385 2026 年 16 卷 1 期 ; MAR 17
收录：
摘要：

Patients with peripheral T cell lymphoma (PTCL) who achieved tumor response with first-line standard therapy were at high risk of disease relapse. We explored golidocitinib (150 mg once daily) as maintenance therapy for this group of patients (JACKPOT26, NCT06511869). This study included two cohorts: patients achieving a complete response (Cohort 1 (CR), N = 30) and a partial response (Cohort 2 (PR), N = 18) during induction stage. All enrolled patients were transplant ineligible or did not have a transplant plan. All dosed patients were included in the efficacy and safety analysis. In Cohort 1, the 24-month disease free survival (DFS) rate was 74.2% with golidocitinib treatment. In nodal subtypes (AITL, NOS, ALK- ALCL), the 24-month DFS rate was 62.7%. In Cohort 2, median progression free survival (PFS) was 17.4 months, and 24-month PFS rate was 48.6%. Nine out of 18 patients with initial PR achieved complete response, leading to a complete response rate of 50.0%, and median duration of response of 23.9 months. The most common >= grade 3 treatment-related treatment-emergent adverse events (TRAEs) were hematological adverse events in nature, including neutrophil count decreased (47.9%), white blood cell count decreased (31.3%), lymphocyte count decreased (14.6%) and leukopenia (12.5%). The majority of these TRAEs were reversible and clinically manageable. TRAEs leading to treatment interruption and discontinuation occurred in 60.4% and 10% of patients, respectively. No TRAEs leading to fatal outcomes were reported. This study suggests the potential of golidocitinib as maintenance therapy for patients with PTCL.
推荐引用方式
GB/T 7714：

Wei Juying,Cai Qingqing,Zhang Liling, et al. Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26) [J].BLOOD CANCER JOURNAL,2026,16(1).
APA：

Wei Juying,Cai Qingqing,Zhang Liling,Zou Liqun,&Jin Jie.(2026).Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26) .BLOOD CANCER JOURNAL,16(1).
MLA：

Wei Juying, et al. "Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)" .BLOOD CANCER JOURNAL 16,1(2026).
入库时间：

4/2/2026 9:30:37 PM
更新时间：

4/9/2026 10:23:37 PM
条目包含文件：

文件类型： , 文件大小：

正在加载全文

未找到全文

浏览次数：17  下载次数：0

分享到：

浏览次数：17

下载次数：0

打印次数：0